ERBB2 and cancer: This ApDC’s in vitro as well as in vivo antitumor efficacy was evaluated in HER2-positive BT-474 and HER2-negative MDA-MB-231 cancer cells and in mice carrying BT-474 breast tumors overexpressing HER2.